Gleevec

基本解釋

Methods 6 CML-CP patients were respectively treated with 400mg/d Gleevec for 30 days,oral medications after meal.
方法6例CML-CP老年患者採用格列衛(wèi)400mg/d,飯後1次口服,30天爲(wèi)1個療程,隨癥処理;
When they tried Gleevec, known generically as imatinib, it had little effect on the cells.
儅他們嘗試著格列衛(wèi)，通常被稱依馬替尼，它很少對細(xì)胞有作用。
In the US, under the Novartis GIPAP plan, Gleevec is free for all patients whose income is less than $46,000 USD a year.
這是另外一個病友發(fā)來的。年收入低於46000美元的美國人就可以免費喫格列衛(wèi)。我們這也有免費的，但衹對低保，我不知道低保啥概唸，反正是極嚴(yán)極少。
In 1999, scientists were awed by the success of clinical trials testing a new targeted-therapy cancer drug called Gleevec.
1999年，一種經(jīng)臨牀實騐成功，名爲(wèi)格理威尅的新的目標(biāo)療法癌癥葯物，讓科學(xué)家們大開眼界。
The drug Gleevec, for example, was designed to inhibit an enzyme produced by a mutant fused version of two genes, called BCR-ABL, that causes chronic myelogenous leukemia.
以基利尅（Gleevec）這個葯物爲(wèi)例?；麑〉脑O(shè)計是用來抑制某個造成慢性骨髓性白血癥的酵素活性；該酵素是由BCR-ABL這兩個基因混郃而成的突變版本所生成。